ABBVIE INC (ABBV) 146.28 -1.12 (-0.76%)
146.28 -1.12 (-0.76%)
US00287Y1091 - Common Stock - After market: 146.4 +0.12 (+0.08%)
AbbVie’s global bestseller Humira to face knockoffs this week (NYSE:ABBV)
After adding $208B in sales over two decades, AbbVie's (ABBV) monopoly over world's best selling drug Humira (adalimumab) is about to end as copycats enter. Read the full story here.
7 Dividend Stocks to Buy Now or You’ll Be Kicking Yourself Later
Dividend stocks are a hedge against volatile markets. Here are seven dividend stocks that you should buy now before you regret missing out.
2 of the Best Dividend Stocks to Own in 2023
You can count on them for passive income and growth over time.
J&J pulls Imbruvica combo filing in EU as EMA cites potential 'serious side effects'
A committee of the European Medicines Agency ((EMA)) said that Johnson & Johnson (JNJ) withdrew its application seeking expanded approval of blood cancer drug Imbruvica on Dec
Interesting ABBV Put And Call Options For March 10th
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.
Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023
/PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World...
3 Reasons to Buy AbbVie and 2 Reasons Not to Buy
The pharmaceutical specialist is facing a pivotal year in 2023, thanks to growing competition.
Want Safety and Growth in 2023? Try These Dividend Stocks.
Passive income is particularly welcome during tough market times.
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.
2 Top Passive-Income Stocks to Own in 2023
These dividend stocks can deliver both downside protection and capital appreciation.
AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry.
Two newer immunology drugs look like big tickets to growth.
AstraZeneca, Biogen, Bristol, and Eli Lilly among companies w/ blockbuster potential drugs
Looking at recently approved drugs and the pipelines of major pharmaceutical companies, there is no lack of therapies that could potentially be significant revenue drivers.Analytics...
Noteworthy Friday Option Activity: IBM, ATVI, ABBV
7 Stocks Every Smart Investor Should Own in 2023
At this point, the best thing to do is position your portfolio for potential downside with these top stocks to own.
3 Unstoppable Stocks to Keep Buying in 2023
These companies have what it takes to drive long-term share performance.
AbbVie Stock: Dividend King ABBV Overview
7 Biotech Stocks That Will Make You Rich in 10 Years
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.
AbbVie's Allergan unit launches new, long-lasting Juvederm dermal filler (NYSE:ABBV)
Allergan Aesthetics, a division of AbbVie (ABBV), has launched nationwide Juvederm Volux XC, long-lasting hyaluronic acid filler for severe loss of jawline definition.
2 Cheap Growth Stocks That Can Set You Up for Life
Over the past 10 years, these stocks have each risen by more than 340%.
See Which Of The Latest 13F Filers Holds AbbVie
Could This FDA Approval Boost AbbVie's Stock?
Last month, one of its anti-psychotic drugs received approval from the Food and Drug Administration for another indication.
SkinMedica® Launches Even & Correct
/PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of the long-awaited SkinMedica® Even & Correct Collection....
With Competition on the Rise, Is AbbVie's Dividend Safe?
This year isn't starting on the best of notes for the drugmaker.
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich
The fountain of youth might not be a myth in the future.
Is AbbVie a Good Dividend Stock to Buy on the Dip?
The stock offers an attractive yield, but investors need to brace for declining revenue this year.
BioMed X, AbbVie extend partnership to focus on immunology research (NYSE:ABBV)
Germany-based research institute BioMed X is broadening an existing partnership with AbbVie (ABBV) to focus on immunology and tissue engineering.
4 High-Yield Dividend Kings For 2023
These 3 Dividend Kings offer value and yield to investors and could outperform the group in 2023. That's good news for income investors.
5 Dividend Kings I Bought for My Portfolio
Rely upon income-generating stocks to see your portfolio through times of upheaval.
AbbVie and Lilly leave U.K. drug pricing deal (NYSE:ABBV)
AbbVie (ABBV) and Eli Lilly (LLY) have left a voluntary drug pricing agreement between the pharma industry and the U.K
Drugmakers Eli Lilly, AbbVie Leave UK Medicine-Pricing Agreement
Drugmakers Eli Lilly & Co. and AbbVie Inc. have pulled out of a voluntary drug-pricing agreement with the UK in a blow to the country’s attempts to control costs for medicines.
Want to Get Richer? 3 Best Stocks to Buy Now and Hold Forever
Steady growth and dividends in an evergreen industry like healthcare can be a winning investment strategy.